Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options

Anti-proliferative activity of CGK012 against multiple myeloma cells via Wnt/β-catenin signaling attenuation

(2017) Pyung jun Choi et al.   LEUKEMIA RESEARCH

β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma

(2017) Ioanna Savvidou et al.   MOLECULAR CANCER THERAPEUTICS

MUC1-C drives MYC in multiple myeloma

(2016) Ashujit Tagde et al.   BLOOD

Genomic complexity of multiple myeloma and its clinical implications

(2016) Salomon Manier et al.   Nature Reviews Clinical Oncology

Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease

(2016) H van Andel et al.   ONCOGENE

Aberrantly expressed LGR4 empowers Wnt signaling in multiple myeloma by hijacking osteoblast-derived R-spondins

(2016) Harmen van Andel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma

(2016) N Bolli et al.   Blood Cancer Journal

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

(2015) Brian A. Walker et al.   JOURNAL OF CLINICAL ONCOLOGY

Wnt addiction of genetically defined cancers reversed by PORCN inhibition

(2015) B Madan et al.   ONCOGENE

Osteoblastic niche supports the growth of quiescent multiple myeloma cells

(2014) Z. Chen et al.   BLOOD

A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events

(2014) Swaminathan P. Iyer et al.   BRITISH JOURNAL OF HAEMATOLOGY

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

(2014) Jens G. Lohr et al.   CANCER CELL

miR-30-5p Functions as a Tumor Suppressor and Novel Therapeutic Tool by Targeting the Oncogenic Wnt/β-Catenin/BCL9 Pathway

(2014) Jian-Jun Zhao et al.   CANCER RESEARCH

Safely targeting cancer stem cells via selective catenin coactivator antagonism

(2014) Heinz-Josef Lenz et al.   CANCER SCIENCE

Targeting the bone marrow microenvironment in multiple myeloma

(2014) Yawara Kawano et al.   IMMUNOLOGICAL REVIEWS

GP130 activation induces myeloma and collaborates with MYC

(2014) Tobias Dechow et al.   JOURNAL OF CLINICAL INVESTIGATION

An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control

(2014) H. Clevers et al.   SCIENCE

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

(2014) Niccolo Bolli et al.   Nature Communications

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

(2013) G. Mulligan et al.   BLOOD

A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutation-Driven Colorectal Tumor Growth

(2013) T. Lau et al.   CANCER RESEARCH

Heparan sulfate proteoglycans in the control of B cell development and the pathogenesis of multiple myeloma

(2013) Rogier M. Reijmers et al.   FEBS Journal

Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease

(2013) Ida B. Kristensen et al.   LEUKEMIA & LYMPHOMA

WNT signaling in bone homeostasis and disease: from human mutations to treatments

(2013) Roland Baron et al.   NATURE MEDICINE

Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma

(2013) X. Jiang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974

(2013) J. Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pharmacological Inhibition of the Wnt Acyltransferase PORCN Prevents Growth of WNT-Driven Mammary Cancer

(2012) K. D. Proffitt et al.   CANCER RESEARCH

Wnt/β-Catenin Signaling and Disease

(2012) Hans Clevers et al.   CELL

Recurrent R-spondin fusions in colon cancer

(2012) Somasekar Seshagiri et al.   NATURE

ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner

(2012) Huai-Xiang Hao et al.   NATURE

Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors

(2012) Bon-Kyoung Koo et al.   NATURE

Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/β-catenin signalling thresholds for tumourigenesis

(2012) M Christie et al.   ONCOGENE

Transcriptional Silencing of the Wnt-Antagonist DKK1 by Promoter Methylation Is Associated with Enhanced Wnt Signaling in Advanced Multiple Myeloma

(2012) Kinga A. Kocemba et al.   PLoS One

Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors

(2012) A. Gurney et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeted Disruption of the BCL9/ -Catenin Complex Inhibits Oncogenic Wnt Signaling

(2012) K. Takada et al.   Science Translational Medicine

Multiple Myeloma Mesenchymal Stem Cells: Characterization, Origin, and Tumor-Promoting Effects

(2011) M. R. Reagan et al.   CLINICAL CANCER RESEARCH

Wnt signaling strength regulates normal hematopoiesis and its deregulation is involved in leukemia development

(2011) T C Luis et al.   LEUKEMIA

Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling

(2011) Wim de Lau et al.   NATURE

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways

(2011) J. Wu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

R-spondins function as ligands of the orphan receptors LGR4 and LGR5 to regulate Wnt/ -catenin signaling

(2011) K. S. Carmon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

AV-65, a novel Wnt/β-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model

(2011) H Yao et al.   Blood Cancer Journal

Myeloma cells suppress osteoblasts through sclerostin secretion

(2011) S Colucci et al.   Blood Cancer Journal

Pharmaceutical inhibition of glycogen synthetase kinase-3  reduces multiple myeloma-induced bone disease in a novel murine plasmacytoma xenograft model

(2010) W. G. Gunn et al.   BLOOD

A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value

(2010) B. A. Walker et al.   BLOOD

Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide

(2010) Chad C. Bjorklund et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Loss of the Tumor Suppressor CYLD Enhances Wnt/β-Catenin Signaling through K63-Linked Ubiquitination of Dvl

(2010) Daniele V.F. Tauriello et al.   MOLECULAR CELL

Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α

(2010) Curtis A Thorne et al.   Nature Chemical Biology

Aurora kinase A is a target of Wnt/ -catenin involved in multiple myeloma disease progression

(2009) J. Dutta-Simmons et al.   BLOOD

The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome

(2009) J. J. Driscoll et al.   BLOOD

Targeting EXT1 reveals a crucial role for heparan sulfate in the growth of multiple myeloma

(2009) R. M. Reijmers et al.   BLOOD

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

(2009) M. Fulciniti et al.   BLOOD

Epigenetic dysregulation of secreted Frizzled-related proteins in multiple myeloma

(2009) E. Jost et al.   CANCER LETTERS

BCL9 Promotes Tumor Progression by Conferring Enhanced Proliferative, Metastatic, and Angiogenic Properties to Cancer Cells

(2009) M. Mani et al.   CANCER RESEARCH

 -Catenin Small Interfering RNA Successfully Suppressed Progression of Multiple Myeloma in a Mouse Model

(2009) E. Ashihara et al.   CLINICAL CANCER RESEARCH

Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling

(2009) Shih-Min A. Huang et al.   NATURE

Small molecule–mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer

(2009) Baozhi Chen et al.   Nature Chemical Biology

Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth

(2008) Y.-W. Qiang et al.   BLOOD

Inhibiting Dickkopf-1 (Dkk1) Removes Suppression of Bone Formation and Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma

(2008) Deborah J Heath et al.   JOURNAL OF BONE AND MINERAL RESEARCH